News About: Pharm. Industry
Listed pharmas’ stock prices dropped by 17% after Hanmi incident
Stock prices of listed pharmaceutical companies collapsed by 17% after the Hanmi Pharm crisis.
Moreover, approximately KRW 9 trillion was studied to evaporate from these listed pharmas’ market capitalization by the ...
Hanmi, “Olmutinib in progress, Phase 3 plan temporarily suspended”When it comes to the ‘the300’s(Money Today)’ article ‘Boehringer already suspended clinical trial this August… did it really not know about it,’ Hanmi Pharm announced on the 7th...
|
Celltrion finds distributor of ‘Truxima & Herzuma’ in North America
A U.S. distributor for the Celltrion’s second and third biosimilars was decided.
A company taking charge in Celltrion products’ overseas marketing, Celltrion Healthcare announced on the 6th it chose a global pharmace...
Merck establishes cutting-edge ‘M Lab Center’ in Song-do, Incheon
On the 6th, Merck announced it will establish M Lab™ Center in one of the fastest-growing biotechnology hub, Song-do, Incheon. The center will provide a sharing experimental environment for close cooperation among Mer...
Lutronic announces R-GEN acquires approval of macular edema treating device
On the 6th, Lutronic(CEO Hae-Ryung Hwang) announced ‘R-GEN’ acquired approval of the world’s first macula treating smart laser from the U.S. FDA. It is the first time for a Korean company to acquire approval of an oph...
Boehringer headquarters, “It is right we notified the cancellation at 7:06pm on 29th”
When it comes to the Hanmi Pharm’s technology export agreement cancellation, the opposite party of the cancellation, Boehringer Ingelheim, has released an official position.
According to a report on the 6th, Boehring...
‘Actualized’ rebate investigation on multinational companies
The industry is paying attention to the Novartis’ rebate crisis since it might be extended to investigations on other multinational pharmaceutical companies.
It was observed the authorities of the Ministry of Health ...
Hanmi Pharm’s side effect incident causes issues to devaluate efforts in new drug dev
While some raise voices to derogate the accumulated performance of the pharmaceutical industry based on the case of Hanmi Pharm having side effects on its antibody, some said the Hanmi Pharm’s case should not be a rea...
Boehringer cancelled agreement with Hanmi because of competing drug’s excellence
It was pointed out Boehringer Ingelheim decided to cancel the technology introduction agreement of ‘olmutinib’ with Hanmi Pharm because of its side effects and excellent results of other competing drugs.
Hyundai Secu...
Pharma companies’ desperate measures, “Work with plain clothes”
Since the enforcement of the Kim Young-Ran Law, medical representatives of pharmaceutical company have been under lots of stress. Even if they are following the law right, they are having trouble meeting doctors showi...
